Effect of Rivaroxaban and Aspirin in Patients with Peripheral Artery Disease Undergoing Surgical Revascularization: Insights from the VOYAGER PAD Trial

Conclusions: The efficacy of rivaroxaban is associated with a benefit in surgical LER patients. While bleeding was increased with rivaroxaban plus aspirin, the incidence was low, with no significant increase in fatal bleeding, intracranial hemorrhage or postprocedural bleeds requiring intervention. Clinical Trial Registration: URL: https://clinicaltrials.gov Unique Identifier: NCT02504216.PMID:34380322 | DOI:10.1161/CIRCULATIONAHA.121.054835

Source: Circulation - August 12, 2021 Category: Cardiology Authors: E Sebastian Debus Mark R Nehler Nicholas Govsyeyev Rupert M Bauersachs Sonia S Anand Manesh R Patel Fabrizio Fanelli Warren H Capell Taylor Brackin Franz Hinterreiter Dainis Krievins Patrice Nault Gabriele Piffaretti Alexei Svetlikov Nicole Jaeger Connie Source Type: research